Kernal Biologics
-53%
est. 2Y upside i
Kernal is creating mRNA 2.0 therapies that work in specific cells
Rank
#763
Sector
Biotechnology
Est. Liquidity
~5Y
Data Quality
Data: MediumKernal Biologics presents a moderate upside opportunity driven by its innovative mRNA 2.0 platform and significant ARPA-H grant for its in vivo CAR T-cell program, but carries high risk typical of early-stage biotech.
Last updated: February 23, 2026
Kernal Biologics achieves significant positive clinical trial results for lead candidates, attracting substantial follow-on investment or a strategic acquisition by a major pharmaceutical company based on early data.
Kernal Biologics demonstrates steady progress in clinical development, secures additional funding rounds, and continues to validate its mRNA 2.0 platform, leading to a moderate increase in valuation.
Clinical trials face setbacks, regulatory hurdles prove challenging, or increased competition from larger players erodes market position, leading to a significant decrease in valuation or difficulty raising further capital.
Preference Stack Risk
highAssuming a current estimated post-money valuation of $300M and approximately $35M in equity funding, the investor take ratio is about 11.7%, indicating a meaningful preference stack ahead of common shareholders. In an exit at or below $35M, common shareholders would likely receive little to nothing.
Dilution Risk
highAs a very high capital intensity, clinical-stage biotech, Kernal Biologics will likely require multiple large funding rounds to advance its pipeline, leading to significant future dilution for current equity holders.
Secondary Liquidity
limitedAccredited investors may have limited opportunities to buy or sell shares through platforms like EquityZen, but a broad, active secondary market for employees is unlikely at this stage.
Community
Valuation Sentiment
Our model estimates -53% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.